Abstract：
:Acute myeloid leukemia (AML) is a complex clonal disorder. The disease is characterized by chromosomal and molecular abnormalities that propagate and expand the abnormal clone(s). The main goal of therapy is to achieve and ultimately maintain a complete remission. In the younger AML patient (less than 60 years of age), there has been a standardization of the initial therapy with the 3 + 7 regimen, consisting of an anthracycline and cytarabine combination. Recent intensification of the anthracycline has led to improved remission and survival outcomes in these patients. Prognosis and therapy in this disease is driven by cytogenetic studies and the additional molecular information that is gathered at the time of diagnosis. With the finding of potential targetable lesions within these molecular aberrancies, new treatments are emerging to deepen remissions and ultimately improve survival.
journal_name
Curr Hematol Malig Repjournal_title
Current hematologic malignancy reportsauthors
Fernandez HFdoi
10.1007/s11899-016-0339-9subject
Has Abstractpub_date
2016-10-01 00:00:00pages
327-32issue
5eissn
1558-8211issn
1558-822Xpii
10.1007/s11899-016-0339-9journal_volume
11pub_type
杂志文章,评审abstract：:High-dose chemotherapy with autologous stem cell transplantation (ASCT) has been shown to improve survival in patients with multiple myeloma in randomized trials and is the standard of care for eligible patients. Recent randomized trials suggest a survival benefit with tandem ASCT, notably for patients failing to achi...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-007-0017-z
更新日期：2007-05-01 00:00:00
abstract：PURPOSE OF REVIEW:In this review article, we will highlight ethical issues faced by hematologists due to a growing constellation of expensive diagnostics and therapeutics in hematology. We outline the important issues surrounding this topic including stakeholders, cost considerations, and various ethical challenges sur...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-020-00599-w
更新日期：2020-10-01 00:00:00
abstract：PURPOSE OF REVIEW:Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare malignancy derived from plasmacyoid dendritic cells whose biology, clinical features, and treatment options are increasingly better understood. RECENT FINDINGS:TCF4 is a master regulator that drives donwstream transcriptional programs in ...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-018-0489-z
更新日期：2018-12-01 00:00:00
abstract：PURPOSE OF REVIEW:Myelodysplastic syndrome (MDS) is a clinically and molecularly heterogeneous disease, which primarily occurs in older adults. Although hypomethylating agents have survival benefit and are the current standard of care, many MDS patients will not garner a response from therapy. For those who do respond,...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-018-0477-3
更新日期：2018-12-01 00:00:00
abstract：:Most non-Hodgkin lymphomas (NHL) are of B-cell origin; only about 10% are T-cell or NK-cell lymphomas. The clinical features of T/NK-cell lymphomas differ from those of B-cell lymphomas: advanced stage and extranodal disease are more common and the prognosis is worse. Several studies have confirmed that 2-[fluorine-18...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章
doi：10.1007/s11899-011-0098-6
更新日期：2011-12-01 00:00:00
abstract：:Chronic myeloid leukemia (CML) arises as a consequence of a chromosomal translocation giving rise to the Philadelphia chromosome and Bcr-Abl oncogene. CML is a clonal disease of stem cell origin and an excellent example of a malignancy in which tumor-initiating cells may hold the key to disease eradication. The known ...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-010-0043-0
更新日期：2010-04-01 00:00:00
abstract：:Acute myeloid leukemia (AML) is a very heterogeneous disease. Prognosis is related not only to intrinsic characteristics such as cytogenetics and molecular markers, but also the patient's ability to tolerate therapy, and treatment response. Allogeneic stem cell transplantation (allo-HCT) has been traditionally indicat...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-014-0207-4
更新日期：2014-06-01 00:00:00
abstract：:Hodgkin lymphoma (HL) is a rare malignancy of the lymphatic system that is curable in at least 80 % of patients. Although patients usually present with painless lymphadenopathy, a variety of systemic and organ-specific syndromes may also exist in relation to HL. These syndromes may develop before, during, or after the...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-012-0131-4
更新日期：2012-09-01 00:00:00
abstract：PURPOSE OF REVIEW:Hematopoietic cell transplant (HCT) patients are required to have a caregiver present for up to 100 days post-transplant. Caregivers provide essential support during HCT but experience immense stress and burden. Increasing research has developed interventions for HCT caregivers. This review systematic...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-018-0445-y
更新日期：2018-06-01 00:00:00
abstract：:The original version of this article unfortunately contained a mistake. The conflict of interest statement was incorrect. The corrected statement is given below. ...
journal_title：Current hematologic malignancy reports
pub_type： 已发布勘误
doi：10.1007/s11899-018-0488-0
更新日期：2019-02-01 00:00:00
abstract：:The clonal blood disorders polycythemia vera, essential thrombocythemia and primary myelofibrosis belong to the BCR-ABL1-negative myeloproliferative neoplasms and are specified by increased production of terminally differentiated myeloid cells. Clonal evolution, disease initiation and progression are influenced by gen...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-013-0184-z
更新日期：2013-12-01 00:00:00
abstract：PURPOSE OF REVIEW:Social media has dramatically changed the access and exchange of information in healthcare and beyond. A variety of platforms and resources exist allowing blood and marrow transplant providers, researchers, and patients to interact. We review the adoption of social media by the transplantation communi...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-018-0487-1
更新日期：2018-12-01 00:00:00
abstract：:Multiple myeloma (MM) is characterized by abnormal proliferation of plasma cells in the bone marrow leading to symptoms of anemia, renal failure, hypercalcemia, and bone lesions. Bone imaging is critical for the diagnosis, staging, assessment for the presence and extent of bone lesions, and initial treatment of MM. Sk...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-017-0379-9
更新日期：2017-06-01 00:00:00
abstract：:Advances in drug discovery have led to the use of effective targeted agents in the treatment of hematologic malignancies. Drugs such as proteasome inhibitors in multiple myeloma and tyrosine kinase inhibitors in chronic myeloid leukemia and non-Hodgkin lymphoma have changed the face of treatment of hematologic maligna...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-017-0369-y
更新日期：2017-06-01 00:00:00
abstract：:Allogeneic hematopoietic cell transplantation (HCT) has curative potential for patients with myelodysplastic syndromes (MDS), though with considerable nonrelapse mortality and morbidity. The International Prognostic Scoring System, despite its confines, remains a widely used tool guiding treatment decisions in MDS. Th...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-009-0035-0
更新日期：2010-01-01 00:00:00
abstract：PURPOSE OF REVIEW:To provide an update on the pathogenesis of enteropathy-associated T cell lymphoma (EATL) and its relationship with refractory celiac disease (RCD), in light of current knowledge of immune, genetic, and environmental factors that promote neoplastic transformation of intraepithelial lymphocytes (IELs)....
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-018-0459-5
更新日期：2018-08-01 00:00:00
abstract：PURPOSE OF REVIEW:Social media has revolutionized the access and exchange of information in healthcare. The microblogging platform Twitter has been used by blood and marrow transplant physicians over the last several years with increasing enthusiasm. We review the adoption of Twitter in the transplant community and its...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-018-0434-1
更新日期：2018-02-01 00:00:00
abstract：:The prognosis value of interim positron emission tomography (PET) remains controversial in diffuse large B-cell lymphoma (DLBCL) patients because of the absence of consensus on criteria able to early identify good and bad responders to treatment. Visual interpretation using the International Harmonization Project (IHP...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-012-0129-y
更新日期：2012-09-01 00:00:00
abstract：PURPOSE OF REVIEW:There are limited treatment options for relapsed/refractory classical Hodgkin lymphoma (cHL) patients who progress on brentuximab vedotin and programmed death-1 inhibitors. Camidanlumab Tesirine (Cami) is a new agent that has shown activity in multiply relapsed/refractory cHL patients. In this review,...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-021-00604-w
更新日期：2021-01-25 00:00:00
abstract：PURPOSE OF REVIEW:Passive immunotherapy with therapeutic monoclonal antibodies (mAbs) has revolutionized the treatment of cancer, especially hematological malignancies over the last 20 years. While use of mAbs has improved outcomes, development of resistance is inevitable in most cases, hindering the long-term survival...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-019-00542-8
更新日期：2019-10-01 00:00:00
abstract：PURPOSE OF REVIEW:The Choosing Wisely® initiative, led by the American Board of Internal Medicine Foundation in collaboration with national professional medical societies, aims to help patients choose care that is essential, free from harm, and evidence-based. The American Society of Hematology has advocated practices ...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-020-00593-2
更新日期：2020-08-01 00:00:00
abstract：PURPOSE OF REVIEW:Antibody-drug conjugates are a new class of therapeutic agents in the treatment of B cell malignancies. In this review, we summarize the recent developments of polatuzumab vedotin in the treatment of relapsed or refractory diffuse large B cell lymphoma (DLBCL) and follicular lymphoma (FL). RECENT FIN...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-020-00572-7
更新日期：2020-04-01 00:00:00
abstract：:Allogeneic haematopoietic cell transplantation continues to be an important curative therapy for acute lymphoblastic leukaemia (ALL). Traditionally accepted indications for allografting adult ALL patients need reevaluation in light of outcomes with paediatric-like intensive regimens. Minimal residual disease status an...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-017-0371-4
更新日期：2017-04-01 00:00:00
abstract：:Although the majority of patients with acute myeloid leukemia (AML) achieve a complete remission with induction chemotherapy, most will ultimately relapse. Therefore, the optimal postremission therapy for AML remains to be defined, and further improvements in treatment strategies are required. Clinical trials have dem...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-006-0021-8
更新日期：2006-06-01 00:00:00
abstract：:The DNA hypomethylating agents (HMAs) azacitidine and decitabine are currently the most frequently administered disease-modifying therapies for patients with higher-risk myelodysplastic syndromes (MDS). However, azacitidine and decitabine are not curative, the median response duration is 11-15 months, and only 10-20 %...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-015-0273-2
更新日期：2015-09-01 00:00:00
abstract：:The introduction of imatinib represented a breakthrough in the treatment of chronic myelogenous leukemia (CML). However, about 20% of patients treated in early chronic-phase CML are off therapy after 6 years because of resistance or intolerance, and most patients taking imatinib remain BCR-ABL-positive at the molecula...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章
doi：10.1007/s11899-008-0012-z
更新日期：2008-04-01 00:00:00
abstract：:BCR-ABL-negative myeloproliferative neoplasms include primary myelofibrosis, polycythemia vera, and essential thrombocythemia. Clonal stem cell proliferation and dysregulated JAK/STAT molecular pathways characterize these hematologic malignancies. Symptoms experienced by patients are heterogeneous including excessive ...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-014-0239-9
更新日期：2014-12-01 00:00:00
abstract：:Patients with acute leukemia who undergo hematopoietic stem cell transplantation (HSCT) are susceptible to malnutrition caused by several factors including intensive cytotoxic therapy. This paper discusses the significance of malnutrition in these patients and provides an overview of nutrition therapy by the oral, ent...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-996-0007-6
更新日期：2006-09-01 00:00:00
abstract：:Compared with acute lymphoblastic leukemia (ALL) in older children, ALL in infants has a dismal outcome because rearrangements of the mixed-lineage leukemia (MLL) gene occur in about 80% of these patients, leading to an aggressive type of leukemia. With most recent therapies, about 50% long-term event-free survival is...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-009-0023-4
更新日期：2009-07-01 00:00:00
abstract：:Hodgkin's lymphoma (HL) is a relatively rare disease accounting for 15 % of all lymphoma. This disease has developed from an incurable disease to the adult malignancy with the most favorable prognosis. With current therapeutic approaches consisting of polychemo- and small-field radiotherapy, up to 80 % of all patients...
journal_title：Current hematologic malignancy reports
pub_type： 杂志文章,评审
doi：10.1007/s11899-015-0262-5
更新日期：2015-09-01 00:00:00
